Drug intelligence / Profile preview

PB006

Development stage: Phase 3
Lead developer: Polpharma Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PB006 is a biosimilar of natalizumab, a monoclonal antibody that targets α4-integrin. It was developed by Polpharma Biologics SA as the first biosimilar monoclonal antibody therapy for multiple sclerosis treatment. PB006 works by blocking the movement of immune cells into the brain and spinal cord, thereby reducing inflammation that drives MS. Clinical trials have demonstrated that PB006 matches the reference natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing-remitting multiple sclerosis (RRMS).

Brand names: Tyruko
Other names: biosim-NTZ

Targets

ITGA4 (Integrin alpha-4)

Beyond the preview

Go deeper on PB006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB006.